Comparative Pharmacology
Head-to-head clinical analysis: DARVON COMPOUND 65 versus VICOPROFEN.
Head-to-head clinical analysis: DARVON COMPOUND 65 versus VICOPROFEN.
DARVON COMPOUND-65 vs VICOPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DARVON COMPOUND-65 contains propoxyphene, a centrally acting opioid agonist with analgesic effects primarily mediated through mu-opioid receptors. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Caffeine is a CNS stimulant with additive analgesic effects.
Hydrocodone is a mu-opioid receptor agonist that activates G-protein coupled opioid receptors, leading to analgesia; ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
1 capsule (propoxyphene HCl 65 mg, aspirin 389 mg, caffeine 32.4 mg) orally every 4 hours as needed for pain; maximum 6 capsules per day.
1 tablet (hydrocodone 5 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
None Documented
None Documented
Propoxyphene: 6-12 hours (mean 8 h); nordextropropoxyphene: 22-30 hours (accumulates with repeated dosing; risk of toxicity)
Hydrocodone: 3.8-4.5 hours (immediate-release); clinical context: analgesic duration correlates with half-life, but may be prolonged in renal/hepatic impairment. Ibuprofen: 2-4 hours (immediate-release); clinical context: anti-inflammatory effect may outlast plasma half-life due to tissue distribution.
Renal: ~90% as propoxyphene and metabolites (nordextropropoxyphene); biliary/fecal: ~10%
Hydrocodone: primarily renal (26% as unchanged drug and metabolites, including norhydrocodone, hydromorphone, and conjugates); less than 5% fecal. Ibuprofen: renal (50-60% as unchanged drug and metabolites, mainly conjugated with glucuronic acid; <10% unchanged); biliary/fecal (minor).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination